Critical Dimension for Stable Self-gravitating Stars in AdS

We study the self-gravitating stars with a linear equation of state, $P=a \rho$, in AdS space, where $a$ is a constant parameter. There exists a critical dimension, beyond which the stars are always stable with any central energy density; below which there exists a maximal mass configuration for a certain central energy density and when the central energy density continues to increase, the configuration becomes unstable. We find that the critical dimension depends on the parameter $a$, it runs from $d=11.1429$ to 10.1291 as $a$ varies from $a=0$ to 1. The lowest integer dimension for a dynamically stable self-gravitating configuration should be $d=12$ for any $a \in [0,1]$ rather than $d=11$, the latter is the case of self-gravitating radiation configurations in AdS space.Comment: Revtex, 11 pages with 7 eps figure

Extremely low long‐term erosion rates around the Gamburtsev Mountains in interior East Antarctica

The high elevation and rugged relief (>3 km) of the Gamburtsev Subglacial Mountains (GSM) have long been considered enigmatic. Orogenesis normally occurs near plate boundaries, not cratonic interiors, and large‐scale tectonic activity last occurred in East Antarctica during the Pan‐African (480–600 Ma). We sampled detrital apatite from Eocene sands in Prydz Bay at the terminus of the Lambert Graben, which drained a large pre‐glacial basin including the northern Gamburtsev Mountains. Apatite fission‐track and (U‐Th)/He cooling ages constrain bedrock erosion rates throughout the catchment. We double‐dated apatites to resolve individual cooling histories. Erosion was very slow, averaging 0.01–0.02 km/Myr for >250 Myr, supporting the preservation of high elevation in interior East Antarctica since at least the cessation of Permian rifting. Long‐term topographic preservation lends credence to postulated high‐elevation mountain ice caps in East Antarctica since at least the Cretaceous and to the idea that cold‐based glaciation can preserve tectonically inactive topography

Novel technique for the CO₂ laser fabrication of optical devices with sub-micrometer ablation depth precision

We present novel techniques for the processing of fibre end face and cladding surfaces using a 9.6 µm CO2 laser. We investigate the effects of pulse duration on process parameters

Sample size determination for external pilot cluster randomised trials with binary feasibility outcomes:a tutorial

Abstract Justifying sample size for a pilot trial is a reporting requirement, but few pilot trials report a clear rationale for their chosen sample size. Unlike full-scale trials, pilot trials should not be designed to test effectiveness, and so, conventional sample size justification approaches do not apply. Rather, pilot trials typically specify a range of primary and secondary feasibility objectives. Often, these objectives relate to estimation of parameters that inform the sample size justification for the full-scale trial, many of which are binary. These binary outcomes are referred to as “feasibility outcomes” and include expected prevalence of the primary trial outcome, primary outcome availability, or recruitment or retention proportions. For pilot cluster trials, sample size calculations depend on the number of clusters, the cluster sizes, the anticipated intra-cluster correlation coefficient for the feasibility outcome and the anticipated proportion for that outcome. Of key importance is the intra-cluster correlation coefficient for the feasibility outcome. It has been suggested that correlations for feasibility outcomes are larger than for clinical outcomes measuring effectiveness. Yet, there is a dearth of information on realised values for these correlations. In this tutorial, we demonstrate how to justify sample size in external pilot cluster trials where the objective is to estimate a binary feasibility outcome. We provide sample size calculation formulae for a variety of scenarios, make available an R Shiny app for implementation, and compile a report of intra-cluster correlations for feasibility outcomes from a convenience sample. We demonstrate that unless correlations are very low, external pilot cluster trials can be made more efficient by including more clusters and fewer observations per cluster

Local free-fall temperature of a RN-AdS black hole

We use the global embedding Minkowski space (GEMS) geometries of a (3+1)-dimensional curved Reissner-Nordstr\"om(RN)-AdS black hole spacetime into a (5+2)-dimensional flat spacetime to define a proper local temperature, which remains finite at the event horizon, for freely falling observers outside a static black hole. Our extended results include the known limiting cases of the RN, Schwarzschild--AdS, and Schwarzschild black holes.Comment: 18 pages, 11 figures, version to appear in Int. J. Mod. Phys.

Thermodynamics of Large AdS Black Holes

We consider leading order quantum corrections to the geometry of large AdS black holes in a spherical reduction of four-dimensional Einstein gravity with negative cosmological constant. The Hawking temperature grows without bound with increasing black hole mass, yet the semiclassical back-reaction on the geometry is relatively mild, indicating that observers in free fall outside a large AdS black hole never see thermal radiation at the Hawking temperature. The positive specific heat of large AdS black holes is a statement about the dual gauge theory rather than an observable property on the gravity side. Implications for string thermodynamics with an AdS infrared regulator are briefly discussed.Comment: 17 pages, 1 figure, v2. added reference

Polypill for prevention of cardiovascular disease in an Urban Iranian population with special focus on nonalcoholic steatohepatitis: A pragmatic randomized controlled trial within a cohort (PolyIran - Liver) – Study protocol

Background: Cardiovascular disease (CVD) is among the most common causes of mortality in all populations. Nonalcoholic steatohepatitis is a common finding in patients with CVD. Prevention of CVD in individual patients typically requires periodic clinical evaluation, as well as diagnosis and management of risk factors such as hypertension and hyperlipidemia. However, this is resource consuming and hard to implement, especially in developing countries. We designed a study to investigate the effects of a simpler strategy: a fixed-dose combination pill consisting of aspirin, valsartan, atorvastatin and hydrochlorthiazide (PolyPill) in an unselected group of persons aged over 50 years. Design: The PolyIran-Liver study was performed in Gonbad city as an open label pragmatic randomized controlled trial nested within the Golestan Cohort Study. We randomly selected 2,400 cohort study participants aged above 50 years, randomly assigned them to intervention or usual care and invited them to participate in an additional measurement study (if they met the eligibility criteria) to measure liver related outcomes. Those agreeing and randomized to the intervention arm were offered a daily single dose of PolyPill. We will follow participants for 5 years. The primary outcome is major cardiovascular events, secondary outcomes include all-cause mortality and liver related outcomes: liver stiffness and liver enzyme levels. Cardiovascular outcomes and mortality will be determined from the cohort study and liver-related outcomes in those consenting to follow up. Analysis will be by allocated group. Trial Status: Between October and December 2011, 1,320 intervention and 1,080 control participants were invited to participate in the additional measurement study. For all these participants, the major cardiovascular events will be determined using blind assessment of outcomes through the cohort study. In the intervention and control arms, 875 (66%) and 721 (67%) respectively, met the eligibility criteria and agreed to participate in the additional measurement study. Liver related outcomes will be measured in these participants. Of the 1,320 participants randomized to the intervention, 787 (60%) accepted the PolyPill. Conclusion: The PolyIran-liver urban study will provide us with important information on the effectiveness of PolyPill on major cardiovascular events, all-cause mortality and liver related outcomes. (ClinicalTrials.gov ID: NCT01245608). © 2015, Academy of Medical Sciences of I.R. Iran. All rights reserved